1-4 of 4
Rod Hicks
Close
Sort by
Journal Articles

Comparing a Novel PET Agent, Yttrium-86 Oxine, with Biopsy and FACS Analysis for Tracking in Vivo Migration Patterns of Different Preparations of DC from a Single Donor

Si mon J. Harrison, PhD, Mick Thompson, Dominic Wall, PhD, Maureen Loudovaris, Andreas Mackensen, MD, Jacques Bartholeyns, Maria Ferrantini, Laura Santodonato, Thomas Felzmann, Rod Hicks, H. Miles Prince, David Ritchie
Journal: Blood
Blood (2008) 112 (11): 5436.
https://doi.org/10.1182/blood.V112.11.5436.5436
Published: 2008
Journal Articles

A Prospective Study of the Prognostic Impact of 18 [F]-FDG-PET and Molecular Response in Patients with Relapsed Indolent Non-Hodgkin Lymphoma (NHL) Following Iodine-131-Rituximab Radio-Immunotherapy (RIT).

Mark J. Bishton, MB, ChB, Rod Hicks, David Alan Westerman, Miles Prince, Max Wolf, John Francis Seymour
Journal: Blood
Blood (2007) 110 (11): 3421.
https://doi.org/10.1182/blood.V110.11.3421.3421
Published: 2007
Journal Articles

In Vivo Tracking of Macrophage Activated Killer Cells to Sites of Metastatic Ovarian Carcinoma.

David S. Ritchie, MBBS, PhD, FRACP, FRCPA, Linda Mileshkin, MBBS, FRACP, Dominic M. Wall, PhD, Jacques Bartholyens, PhD, Mick Thompson, BSc, Rod Hicks, MBBS, MD, FRACP, Miles Prince, MBBS, MD, FRACP, FRCPA
Journal: Blood
Blood (2005) 106 (11): 3874.
https://doi.org/10.1182/blood.V106.11.3874.3874
Published: 2005
Journal Articles

A Mid-Treatment FDG-Positron Emission Tomography (PET) Scan Is Highly Predictive of Subsequent Treatment Failure in Patients with Diffuse Large B-Cell Lymphoma (DLBCL).

Ashley P. Ng, Michael Lee, Annette Hogg, John F. Seymour, Henry Janusewicz, Miles Prince, Michael MacManus, Rod Hicks, Andrew Wirth
Journal: Blood
Blood (2005) 106 (11): 1931.
https://doi.org/10.1182/blood.V106.11.1931.1931
Published: 2005